Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

48.11 +0.49 (+1.03%)
Official Closing Price Updated: 7:00 PM EDT, Aug 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 8,328,419
Open 47.67
Bid (Size) 48.03 (2)
Ask (Size) 48.19 (10)
Prev. Close 47.62
Today's Range 47.38 - 48.24
52wk Range 39.35 - 63.41
Shares Outstanding 2,222,113,553
Dividend Yield 4.74%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Cancer Medicines From Merck, Bristol Myers And BeiGene In Question, As FDA Committee To Discuss Limiting PD-1 Drugs For Stomach Cancer
The FDA's Oncologic Drugs Advisory Committee will meet on September 26 to reevaluate the approvals of checkpoint inhibitors for advanced gastric, gastroesophageal junction adenocarcinoma, and... 
Via Benzinga
Exposures Product Safety
Key Takeaways From Bristol-Myers Squibb Analyst Ratings
Via Benzinga

Performance

YTD
-8.81%
-8.81%
1 Month
+7.73%
+7.73%
3 Month
+16.66%
+16.66%
6 Month
-6.87%
-6.87%
1 Year
-21.49%
-21.49%

More News

Read More
Bristol-Myers Squibb's Options Frenzy: What You Need to Know
Via Benzinga
Bristol Myers Squibb Receives U.S. Food and Drug Administration sBLA Acceptance for First-Line Treatment of Unresectable Hepatocellular Carcinoma
From Bristol Myers Squibb
Via Business Wire
Check Out What Whales Are Doing With BMY
Via Benzinga
Smart Money Is Betting Big In BMY Options
Via Benzinga
Smart Money Is Betting Big In BMY Options
Via Benzinga
Merck's Stock Dip Offers a Buying Opportunity: Here’s Why
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
3 High-Yield Dividend Stocks You Can Buy With $200 Now and Hold at Least a Decade
Via The Motley Fool
European Medicines Agency Validates Bristol Myers Squibb’s Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
From Bristol Myers Squibb
Via Business Wire
Where Will Bristol Myers Squibb Be in 5 Years?
Via The Motley Fool
3 High-Yield Dividend ETFs to Buy to Generate Passive Income
Via The Motley Fool
Topics ETFs
Biden Administration Targets $6B Savings Through Medicare Drug Price Negotiations
Via Benzinga
Topics Economy
Exposures Interest Rates
Bristol Myers' German Partner Evotec Plans Layoffs, Cites 'Challenging Revenues, Profitability'
Via Benzinga
Topics Workforce
Exposures Layoff
Cancer-Focused Syros Pharmaceuticals Stops Mid-Stage Leukemia Combo Therapy Study, Cites Disappointing Unexpected Outcome
Via Benzinga
The 3 Best Healthcare Stocks to Buy in August 2024
Via InvestorPlace
Bristol-Myers Squibb Co: Is It A Buy?
Via Talk Markets
3 Stocks Retirees Should Absolutely Love
Via The Motley Fool
3 Biotech Stocks With Promising Drug Pipelines: August 2024
Via InvestorPlace
Exposures Product Safety
Bristol Myers Squibb Terminates Cancer Drug Development Program With Agenus
Via Benzinga
Worried About a Market Correction? 2 High-Yield Dividend Stocks You Can Buy Now and Hold Forever.
Via The Motley Fool
MarketBeat Week in Review – 7/29 - 8/2
Via MarketBeat
Topics Economy Stocks
Exposures Interest Rates US Equities
The 3 Biggest Earnings Beats for Q2 as of August 1, 2024
Via InvestorPlace
Topics Earnings
Exposures Financial
8 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Bargain-Hunters Paradise: 7 Value Stocks That Are Too Cheap to Ignore
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.